FLT3 and acute myeloid leukemia: With the approval of midostaurin as up-front therapy for FLT3-ITD AML, new trials are emerging to better clarify the role of post-transplant TKI therapy in patients with deeper molecular remission, such as the large, phase 3, multinational, randomized trial assessing gilteritinib vs placebo as post-transplant adjuvant therapy for patients with FLT3-ITD AML in CR1 (BMT-CTN 1506; NCT02997202).